EIP is an innovative Intellectual Property law firm advising on all areas of IP. EIP has more than 60 professional staff practising from its four UK offices in Bath, Cardiff, Leeds and London, its US office in Denver and its German office in Dusseldorf. EIP Life is our life sciences and medical devices team which has a wealth of technical knowledge and experience in dealing with the biotechnology and health sectors, for start-ups and major multinationals.
Lilly is developing a growing portfolio of best in class pharmaceutical products by applying the latest research from our own laboratories and from collaborations with eminent scientific organisations worldwide. In 2003 the company's world-wide sales were more than $12 billion. Lilly employs more than 43000 people worlwide and markets medicines in 158 countries. Lilly Research Laboratories (the R&D division of the company) employs more than 8000 people from a wide variety of disciplines. The company has R&D facilities in 9 countries and currently conducts clinical trials in more then 60 countries around the world. . . Lilly's internal research efforts are focused in the following major therapeutic areas: cancer, cardiovascular diseases, endocrinology, neuroscience, gene regulation, bone biology, immunomodulation and Inflammation Compounds in late stage development, and those currently being launched have promise to address the needs of patients with sepsis, cancer, diabetes, depression, osteoporosis, erectile dysfunction, urinary incontinence and attention deficit hyperactivity disorder.. . In pursuit of innovation Lilly seeks to incorporate those cutting edge technologies which support the high quality, rapid identification and investigation of novel compounds.. . The company approach to innovation includes a commitment to the philosophy of research without walls - a stated commitment to partnership and external collaboration. Currently Lilly Research Laboratories has more than 120 active collaborations with external scientists.
Watch our Member Showcase video here https://bit.ly/3HZGpJI
The mission of EMBL-EBI is to: provide freely available data and bioinformatics services to all facets of the scientific community in ways that promote scientific progress; contribute to the advancement of biology through basic investigator-driven research in bioinformatics; provide advanced bioinformatics training to scientists at all levels; and help disseminate cutting-edge technologies to industry. . The research and service activities of EMBL-EBI span the entire spectrum of life science and remain at the cutting edge of the computational sciences. All our major data resources are the products of international collaborations. We work with other data providers to ensure that our data repositories, and those of our collaborators, are comprehensive and up to date. We also actively participate in international efforts to develop data standards.. . The EMBL-EBI Industry Programme engages our industrial users with the latest bioinformatics research, service development, standards activities, pre-competitive opportunities and training https://www.ebi.ac.uk/industry.
Empyrean Therapeutics is focused on developing next generation off-the-shelf cell therapies to enable global and affordable cures for cancer and rare disease. We are building unique technologies, cellular assets and engineering processes which combine to deliver a powerful platform for rapidly manufacturing cellular drugs with novel disease fighting properties. . . Headquartered at the Babraham Research Campus, south of Cambridge, and working with leading clinical partners and academic experts, we are combining world class skills in gene editing with expertise in stem cell programming and precise genetic control to unlock the true potential of designer cellular medicines.
No data available
Strategic and finance advisory
Immunotherapeutics company targeting a new class of tumour specific antigens
Eramol | UK Sterile Fill-Finish and Non-Sterile Pharmaceutical Manufacturing CMO
Eramol is an independent UK and EU pharmaceutical contract manufacturing organisation supporting biotechnology, pharmaceutical, academic and investigator-led clinical programmes. Founded, owned and led by Qualified Persons, Eramol provides integrated pharmaceutical manufacturing and clinical-supply services across sterile and non-sterile drug products. Sponsors can access GMP manufacturing, clinical packaging, labelling, QC testing, QP certification, storage and global distribution through one accountable partner.
Sterile fill-finish and injectable manufacturing
Eramol’s purpose-built Sevenoaks facility provides early-phase sterile fill-finish services for injectable drug products, with a focus on Phase I and Phase II clinical-trial supply.
The facility has been designed around EU GMP Annex 1 principles and includes Grade A isolator technology, closed single-use processing, sterile filtration, aseptic processing and moist-heat terminal sterilisation.
Eramol’s aseptic fill-finish capability with <0.1% line losses is engineered to protect scarce and high-value drug substance. This is particularly valuable for early-phase biologics, monoclonal antibodies, antibody-drug conjugates, peptides, oligonucleotides, RNA therapeutics, viral vectors and other complex injectable products where conventional filling losses can materially affect programme cost and available clinical supply.
The flexible small-batch model supports sterile vials, cartridges and pre-filled syringes, with manufacturing designed for programmes requiring technical agility, high filling accuracy and maximum product recovery.
Non-sterile pharmaceutical manufacturing
Eramol’s established Sevenoaks non-sterile pharmaceutical manufacturing facility supports clinical development through to commercial supply.
GMP manufacturing capabilities include:
• Active and placebo tablets
• Coated and uncoated tablets
• Hard-shell capsules
• API neat-fill capsules
• Over-encapsulation and comparator blinding
• Oral solutions and suspensions
• Placebo development and sensory matching
• Clinical and commercial batch manufacture
The facility supports Phase I, Phase II and Phase III programmes, together with commercial manufacturing requirements. Integrated placebo manufacture and blinding capabilities help sponsors maintain study integrity across complex randomised clinical trials.
Integrated clinical manufacturing and supply
Eramol combines sterile and non-sterile manufacturing with clinical packaging services, multilingual labelling, analytical testing, stability support and regulatory oversight.
In-house Qualified Persons provide UK and EU QP release and certification for clinical and commercial products. Through its UK facilities and Dublin EU hub, Eramol can support manufacture, importation, certify and release for supply across the United Kingdom and European Union.
Following QP release, Eramol provides clinical storage and global pharmaceutical distribution, including controlled ambient, refrigerated and frozen storage, validated cold-chain distribution, direct-to-site supply and international clinical logistics.
This integrated model gives sponsors one experienced partner from pharmaceutical manufacturing through to QP release and delivery to clinical sites.
Watch the video here: https://shorturl.at/8VmLC
For more information see: https://eramol.com/ & https://eramol.com/clinical-services-category/sterile-fill-finish/
Eramol is an independent UK and EU pharmaceutical contract manufacturing organisation supporting biotechnology, pharmaceutical, academic and investigator-led clinical programmes. Founded, owned and led by Qualified Persons, Eramol provides integrated pharmaceutical manufacturing and clinical-supply services across sterile and non-sterile drug products. Sponsors can access GMP manufacturing, clinical packaging, labelling, QC testing, QP certification, storage and global distribution through one accountable partner.
Sterile fill-finish and injectable manufacturing
Eramol’s purpose-built Sevenoaks facility provides early-phase sterile fill-finish services for injectable drug products, with a focus on Phase I and Phase II clinical-trial supply.
The facility has been designed around EU GMP Annex 1 principles and includes Grade A isolator technology, closed single-use processing, sterile filtration, aseptic processing and moist-heat terminal sterilisation.
Eramol’s aseptic fill-finish capability with <0.1% line losses is engineered to protect scarce and high-value drug substance. This is particularly valuable for early-phase biologics, monoclonal antibodies, antibody-drug conjugates, peptides, oligonucleotides, RNA therapeutics, viral vectors and other complex injectable products where conventional filling losses can materially affect programme cost and available clinical supply.
The flexible small-batch model supports sterile vials, cartridges and pre-filled syringes, with manufacturing designed for programmes requiring technical agility, high filling accuracy and maximum product recovery.
Non-sterile pharmaceutical manufacturing
Eramol’s established Sevenoaks non-sterile pharmaceutical manufacturing facility supports clinical development through to commercial supply.
GMP manufacturing capabilities include:
• Active and placebo tablets
• Coated and uncoated tablets
• Hard-shell capsules
• API neat-fill capsules
• Over-encapsulation and comparator blinding
• Oral solutions and suspensions
• Placebo development and sensory matching
• Clinical and commercial batch manufacture
The facility supports Phase I, Phase II and Phase III programmes, together with commercial manufacturing requirements. Integrated placebo manufacture and blinding capabilities help sponsors maintain study integrity across complex randomised clinical trials.
Integrated clinical manufacturing and supply
Eramol combines sterile and non-sterile manufacturing with clinical packaging services, multilingual labelling, analytical testing, stability support and regulatory oversight.
In-house Qualified Persons provide UK and EU QP release and certification for clinical and commercial products. Through its UK facilities and Dublin EU hub, Eramol can support manufacture, importation, certify and release for supply across the United Kingdom and European Union.
Following QP release, Eramol provides clinical storage and global pharmaceutical distribution, including controlled ambient, refrigerated and frozen storage, validated cold-chain distribution, direct-to-site supply and international clinical logistics.
This integrated model gives sponsors one experienced partner from pharmaceutical manufacturing through to QP release and delivery to clinical sites.
Watch the video here: https://shorturl.at/8VmLC
For more information see: https://eramol.com/ & https://eramol.com/clinical-services-category/sterile-fill-finish/
Ernst & Young is also a global leader in professional services with some 114,000 people based in 140 countries. Around the world the firm is committed to pursuing the highest levels of integrity, quality, and professionalism in delivering a broad inventory of services to our clients. Our services fall under three broad headings: Assurance and Advisory Business Services (AABS), Transaction Advisory Services (TAS) and Taxation Services. Our 'account-centric' organisational model recognises that many client issues are best addressed by a number of our service lines working together.. Ernst & Young UK comprises approximately 470 partners and 8000 staff. In 2006 UK fee income increased by 20% to £1.13bn whilst staff numbers excluding partners increased by 8% to 7,902. We provided services to 84 of the FTSE 100 companies and 93% of our clients indicated they were satisfied or very satisfied with our service. For the second year running, we qualified for the Per Cent Standard, meaning that we gave more than 1% of our notional pre-tax profits to charity and we ranked 61st in the Business in the Community's Environment Index.. . COMMITMENT TO BIOTECHNOLOGY. For the past 20 years, Ernst &Young has been a leading professional services firm serving the biotechnology industry, thanks to our extensive global network of experienced professionals and our industry-leading annual publication, Beyond Borders: The Global Biotechnology Report.. Now recognised as the industry bible, Ernst & Young's global biotechnology report, Beyond Borders, provides an overview of the latest developments in the global biotechnology sector. Our report demonstrates that on the cusp of its 30th birthday, the biotech industry is maturing rapidly, with solid financial performance and a substantial track record of bringing new products to market. The contents and themes of this report derive from substantial research by our Global Biotechnology Center, and more importantly, from our leading position serving prominent biotechnology companies around the world.. The life sciences industry is widely acknowledged as one of the leading industries in the future global economy, Ernst & Young has helped shape the global life sciences industry since its inception, advising more of its leading companies than any other professional service firm. We advise one third of life sciences companies globally, have a global network of life sciences specialists in 17 European countries, and boast the UK's largest dedicated life sciences team which our Cambridge office forms part of.. We are reporting accountants to companies in respect of their IPOs on AIM, the London Stock Exchange, and NASDAQ, and are experts in providing tax planning advice for companies seeking IPOs including share option planning.. . CONTACTS:. Julian Jenkins (Audit Partner). 01223 557073. Cathy Taylor (Tax Partner). 01223 557090. Simon Gillings (Transaction Support). 01223 557071